INCYTE CORPORATION |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 52.72 USD | -0.94% |
|
-4.15% | -16.04% |
Financials (USD)
| Sales 2024 * | 4.14B | Sales 2025 * | 4.61B | Capitalization | 11.95B |
|---|---|---|---|---|---|
| Net income 2024 * | 815M | Net income 2025 * | 1.02B | EV / Sales 2024 * | 1.83 x |
| Net cash position 2024 * | 4.37B | Net cash position 2025 * | 5.68B | EV / Sales 2025 * | 1.36 x |
| P/E ratio 2024 * |
15.3
x | P/E ratio 2025 * |
11.9
x | Employees | 2,524 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.41% |
More Fundamentals
* Assessed data
More news
Latest transcript on Incyte Corporation
More recommendations
More press releases
More news
| 1 day | -0.94% | ||
| 1 week | -4.15% | ||
| Current month | -7.46% | ||
| 1 month | -8.06% | ||
| 3 months | -14.25% | ||
| 6 months | -7.82% | ||
| Current year | -16.04% |
1 week
52.70
55.99
1 month
52.7059.03
Current year
52.7067.37
1 year
50.2775.74
3 years
50.2788.26
5 years
50.27110.37
10 years
43.44153.15
| Managers | Title | Age | Since |
|---|---|---|---|
Herve Hoppenot
CEO | Chief Executive Officer | 64 | 14-01-12 |
| Director of Finance/CFO | 53 | 19-02-10 | |
Pablo Cagnoni
PSD | President | 60 | 23-06-04 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Julian Baker
BRD | Director/Board Member | 57 | 00-12-31 |
Edmund Harrigan
BRD | Director/Board Member | 71 | 19-12-15 |
| Director/Board Member | 70 | 15-01-19 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 14.55% | 215 M€ | +12.15% | - | |
| 2.94% | 1 M€ | -1.52% | - | |
| 2.88% | 1 M€ | 0.00% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-17 | 52.72 | -0.94% | 2,525,527 |
| 24-04-16 | 53.22 | -0.39% | 1,465,377 |
| 24-04-15 | 53.43 | -0.78% | 1,574,419 |
| 24-04-12 | 53.85 | -1.95% | 1,227,465 |
| 24-04-11 | 54.92 | -0.15% | 1,580,963 |
Delayed Quote Nasdaq, April 17, 2024 at 04:00 pm EDT
More quotes
Incyte Corporation specializes in the research & development of therapeutic products mainly intended for the treatment of cancers and inflammatory disorders. Net sales break down by revenue source as follows:
- product sales (85.6%);
- royalties (14.2%);
- income from research and cooperation agreements (0.2%).
Sector
Pharmaceuticals
Calendar
2024-04-30
- Q1 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
23
Last Close Price
53.22
USD
Average target price
76.06
USD
Spread / Average Target
+42.91%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -16.04% | 11.95B | |
| -4.89% | 85.08B | |
| +2.11% | 40.14B | |
| -25.74% | 28.37B | |
| +51.96% | 24.07B | |
| -6.17% | 17.24B | |
| -31.09% | 13.85B | |
| -6.58% | 12.29B | |
| -4.19% | 8.02B | |
| +7.08% | 7.73B |
- Stock Market
- Equities
- INCY Stock
